NCT02662751Recruiting
Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke / TIA
The Impact of Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke or Transient Ischemic Attack in Comparison With Usual Care: a Randomized, Controlled, Open Trial
Source: ClinicalTrials.gov · Last updated 10 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The main objective of this study is to compare two post-stroke/TIA (transient ischemic attack) imaging strategies in terms of the number of clinically important (i.e. requiring specific treatment according to current recommendations) lesions detected. The first strategy is the current/usual strategy in each participating centre and the second strategy consists in starting the post-stroke/TIA imaging assessment by a whole-body, low-dose angiography and subsequently resorting to elements of the usual strategy if required.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 260 (estimated)
- First submitted
- 17 Nov 2015
- Start date
- 21 Oct 2019
- Primary completion date
- 12 Jun 2026
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Diseases
- Stroke
- NCT number
- NCT02662751
What you commit to
- Study type: Interventional
- Planned participants: 260
- From 21 Oct 2019 to the primary completion date, 12 Jun 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The patient is currently participating in or has participated in another biomedical research study within the past three months or is currently in an exclusion period determined by a previous study.
- The patient has already undergone a full body scanner in the previous three months
Other illness
- Known allergy to contrast medium or severe allergy to iodine
- Known active malignancy or history of cancer treatment
- History of severe symptomatic cardiovascular event (myocardial infarction, aortic dissection, mesenteric ischemia, renal ischemia)
Lab values
- Renal failure with creatinine clearance below 60 ml / min
Other
- Patient under guardianship or judicial protection
- Refusal to sign the consent
- Inability to correctly inform the patient or his/her trusted person about the study
- The patient is pregnant, parturient, or breastfeeding
- The patient has a contraindication for a treatment used in this study
- Monoclonal immunoglobulin
- Emergency situations that hamper the planned course of the study
Who the study is looking for
- The patient was informed about the implementation of the study, its objectives, constraints and patient rights
- The patient has given free and informed consent and signed the consent
- Patient affiliated with or beneficiary of a health insurance plan
- Patient available for 36 months of follow-up
- The patient has had a stroke (within the past 10 days, diagnosis confirmed by MRI with a diffusion sequence) or transient ischemic attack (within the past 10 days, ABCD2 score greater than 3) without haemorrhage
Age in the registry: 18 years to 89 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHRU de Montpellier, Hopital Gui de Chauliac Coordinator of this site? Confirm its status | Montpellier | France | Recruiting |
| CHRU de Nîmes - Hôpital Universitaire Carémeau Coordinator of this site? Confirm its status | Nîmes | France | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.